Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated...

Area of Science:

• Neuroscience
• Pharmacology
• Cognitive Science

Background:

• Chronic low-dose MPTP administration induces cognitive deficits in monkeys, mimicking aspects of Parkinson's disease.
• MPTP exposure impairs performance on tasks requiring attention and short-term memory, such as the variable delayed response (VDR) task.

Purpose of the Study:

• To investigate the impact of chronic low-dose MPTP on cognitive tasks, specifically the VDR task.
• To evaluate the efficacy of SIB-1508Y, a novel nicotinic acetylcholine receptor agonist, and levodopa in ameliorating MPTP-induced cognitive deficits.

Main Methods:

• Monkeys were administered chronic low-dose MPTP.
• Cognitive performance was assessed using the VDR task, delayed matching-to-sample, and visual pattern discrimination.
• The effects of SIB-1508Y and levodopa were evaluated on task performance post-MPTP treatment.

Main Results:

• MPTP treatment shifted VDR task performance to a delay-independent pattern, indicating deficits in short-delay trials.
• Deficits were observed in delayed matching-to-sample tasks, while visual discrimination remained intact.
• SIB-1508Y significantly improved performance on short-delay VDR trials and delayed matching-to-sample tasks, with effects lasting 24-48 hours. Levodopa and nicotine showed no significant improvement.

Conclusions:

• Chronic low-dose MPTP exposure causes significant cognitive disturbances.
• SIB-1508Y effectively corrects these cognitive deficits, suggesting its therapeutic potential.
• SIB-1508Y may be a viable treatment for cognitive impairments associated with Parkinson's disease, whereas levodopa is not.